NorthStrive Biosciences plans FACS study for EL-22 probiotic candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression
July 10, 2026 7:30 AM EDTIndependent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd.
Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists
NEWPORT BEACH, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (NorthStrive Biosciences), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (PMGC or the Company), today announced plans to initiate an... More
